Volume 1 - Supplement Issue 1: Abstracts of International Tehran Breast Cancer Congress                   MCI 2017, 1 - Supplement Issue 1: Abstracts of International Tehran Breast Cancer Congress: 0-0 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yazdi Samadi F, Mohammadi Z. Chitosan-Raloxifene Nanoparticles as a Novel Double Effect Targeting Vehicle for Breast Cancer Cells. MCI. 2017; 1
URL: http://mcijournal.com/article-1-116-en.html
Abstract:   (330 Views)
Introduction: Chemotherapeutic drugs such as doxorubicin (DOX) due to their extensive
distribution in both healthy and cancerous cells, lead to severe side effects. One of the
most effective ways to overcome this problem is targeting delivery. Particular characteristics
of chitosan such as cationic nature make its nanoparticles one of the best options for
using as targeting drug carriers. Since nearly 75% of breast cancer cells express the estrogen
receptor (ER), blocking the ER function (using ER antagonists such as Raloxifene) seems
to be effective on reducing the risk of progress in breast cancer. In this study, a novel double
effect nanoparticle based on raloxifene-chitosan conjugate was prepared for adjuvant
therapy and drug targeting to breast cancer cells via ER receptor.
Materials and Methods: CS-RAL NPs containing DOX hydrochloride were prepared by
ionotropic gelation method and characterized by Nanozetasizer and TEM. The effect of
nanoparticles on cell viability was evaluated using XTT assay. Moreover, inhibition tests
were performed by means of Estradiol as the main ligand of estrogen receptor.
Results: CS-RAL NPs containing DOX hydrochloride have sizes between 25-35 nm and
desired zeta potentials. XTT assay on MCF-7 cell line illustrated that nanoparticles containing
doxorubicin could inhibit the cellular growth up to 60%. Results from inhibition
tests showed that in the presence of Estradiol the cell toxicity of prepared nanoparticles
decrease significantly.
Conclusions: This study introduced Raloxifene-Chitosan nanoparticles as a novel targeting
agent for adjuvant therapy of breast cancer.
Full-Text [PDF 61 kb]   (101 Downloads)    
Type of Study: Original/Research Article | Subject: genetics
Received: 2017/10/29 | Accepted: 2017/10/29 | ePublished: 2017/10/29

Add your comments about this article : Your username or Email:
Write the security code in the box

© 2015 All Rights Reserved | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb